Bajaj Healthcare Ltd (IN:BAJAJHCARE)
:BAJAJHCARE
Want to see IN:BAJAJHCARE full AI Analyst Report?
BAJAJHCARE Stock Chart & Stats
₹418.50
-₹31.80(-5.51%)
At close: 4:00 PM EST
₹418.50
-₹31.80(-5.51%)
Day’s Range― - ―
52-Week Range₹273.15 - ₹642.30
Previous CloseN/A
Volume215.90K
Average Volume (3M)4.99K
Market Cap
₹11.23B
Enterprise Value₹13.34B
Total Cash (Recent Filing)₹140.05M
Total Debt (Recent Filing)₹2.38B
Price to Earnings (P/E)20.9
Beta1.09
Next Earnings
Jun 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.24%
Share Statistics
EPS (TTM)4.96
Shares Outstanding31,583,252
10 Day Avg. Volume2,706
30 Day Avg. Volume4,987
Financial Highlights & Ratios
PEG Ratio-0.38
Price to Book (P/B)4.64
Price to Sales (P/S)3.98
P/FCF Ratio-124.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained revenue growth of ~17% shows underlying demand for both APIs and formulations. Over a 2–6 month horizon this supports utilization, scale benefits, and bargaining power with suppliers and customers, improving prospects for stable top-line expansion if maintained.
Diversified Business ModelA dual focus on API/intermediates and finished formulations plus domestic and export channels creates durable revenue diversification. This reduces single-market or product risk, supports cross-sell and contract manufacturing growth, and cushions against demand swings in any one segment.
Profitability RecoveryRecovery to a positive net margin after a loss indicates operational adjustments or pricing improvements that restored profitability. If margin normalization continues, it enhances cash generation potential and signals management ability to stabilize earnings through cost or mix improvements.
Bears Say
High LeverageElevated leverage limits financial flexibility and raises refinancing and interest-rate risks over the medium term. With significant debt, the company faces constrained capacity to invest in capacity, R&D or regulatory compliance, increasing vulnerability to revenue or cash-flow shocks.
Weak Cash ConversionInconsistent operating cash flow and negative free cash flow indicate difficulties converting accounting profits into spendable cash. This structural weakness forces reliance on external financing, raising costs and limiting sustainable investment, dividends, and debt reduction ability.
Margin Pressure & Revenue VolatilityDeclining gross and EBIT margins alongside fluctuating revenue point to persistent cost pressures, pricing stress or product-mix swings. These trends can erode earnings quality and make medium-term margin recovery harder without structural cost controls or higher-value product shifts.
Bajaj Healthcare Ltd News
BAJAJHCARE FAQ
What was Bajaj Healthcare Ltd’s price range in the past 12 months?
Bajaj Healthcare Ltd lowest stock price was ₹273.15 and its highest was ₹642.30 in the past 12 months.
What is Bajaj Healthcare Ltd’s market cap?
Bajaj Healthcare Ltd’s market cap is ₹11.23B.
When is Bajaj Healthcare Ltd’s upcoming earnings report date?
Bajaj Healthcare Ltd’s upcoming earnings report date is Jun 02, 2026 which is in 46 days.
How were Bajaj Healthcare Ltd’s earnings last quarter?
Bajaj Healthcare Ltd released its earnings results on Jan 16, 2026. The company reported ₹4.963 earnings per share for the quarter, beating the consensus estimate of N/A by ₹4.963.
Is Bajaj Healthcare Ltd overvalued?
According to Wall Street analysts Bajaj Healthcare Ltd’s price is currently Overvalued.
Does Bajaj Healthcare Ltd pay dividends?
Bajaj Healthcare Ltd pays a Annually dividend of ₹1 which represents an annual dividend yield of 0.24%. See more information on Bajaj Healthcare Ltd dividends here
What is Bajaj Healthcare Ltd’s EPS estimate?
Bajaj Healthcare Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bajaj Healthcare Ltd have?
Bajaj Healthcare Ltd has 31,583,252 shares outstanding.
What happened to Bajaj Healthcare Ltd’s price movement after its last earnings report?
Bajaj Healthcare Ltd reported an EPS of ₹4.963 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.8%.
Which hedge fund is a major shareholder of Bajaj Healthcare Ltd?
Currently, no hedge funds are holding shares in IN:BAJAJHCARE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bajaj Healthcare Ltd
Bajaj HealthCare Limited, a pharmaceutical company, develops, manufactures, and supplies amino acids, nutritional supplements, and active pharmaceutical ingredients (APIs) for pharmaceutical, nutraceuticals, and food industries in India and internationally. The company's product portfolio consists of various APIs in the therapeutic categories of anti-diabetic, antibiotic, antiviral, antiplatelet, antifungal, antihelmintic, iron-chelating agent, anticonvulsant, growth stimulant, non-steroidal anti-inflammatory drugs, antihypertensive, anthelmintics, anti-asthmatic, antioxidant, urinary tract infection, anti-histamine, weight reducing, venous disease, antimalarial, vitamin c, disinfectant/ antiseptic, stimulant, anticonvulsant, lipotropic agents, nootropic, vasoprotective/ antihemorrhagic, cardiovascular agent, food supplements, anti-anemic, amino acids, antiasthmatic / bronchodilator, nutritional supplement, and minerals. It also provides formulations in the form of tablets, capsules, and powder, as well as impurities. In addition, the company exports its products. Bajaj HealthCare Limited was incorporated in 1993 and is based in Thane, India.
Technical Analysis
Bliss Gvs Pharma Limited
―
Hester Biosciences Limited
―
Jagsonpal Pharmaceuticals Ltd.
―
Syncom Formulation (India) Ltd.
―
Themis Medicare Limited
―